A Study of Dexmedetomidine Pharmacokinetics for Preoperative Sedation

Sponsor
Eye & ENT Hospital of Fudan University (Other)
Overall Status
Completed
CT.gov ID
NCT03800641
Collaborator
(none)
45
1
3
12.4
3.6

Study Details

Study Description

Brief Summary

Proper preoperative sedation can reduce patients' anxiety, enhance patients' cooperation and reduce perioperative complications. The investigators would explore the sedative effects of dexmedetomidine (DEX) with the administration of oral, intravenous and nasal drops, and detect DEX blood concentration in 15 participants, respectively. Pharmacokinetic parameters are detected at 8 time points ( before DEX administration, 10 min, 20 min, 30 min, 45 min, 60min, 90min and 120 min after administration). 3 ml arterial blood was collected at each time point. The blood samples are detected by mass spectrometer. The aim of this study is to investigate appropriate administration time and route for DEX sedation.

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
45 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
A Study of Dexmedetomidine Pharmacokinetics for Preoperative Sedation With Administration of Oral, Intravenous and Nasal Drops
Actual Study Start Date :
Jan 11, 2019
Actual Primary Completion Date :
Mar 29, 2019
Actual Study Completion Date :
Jan 23, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: oral administration

oral administration of dexmedetomidine 4μg/kg

Drug: Dexmedetomidine
oral, intravenous and nasal administration of Dexmedetomidine

Active Comparator: intravenous administration

intravenous administration of dexmedetomidine 0.8μg/kg

Drug: Dexmedetomidine
oral, intravenous and nasal administration of Dexmedetomidine

Experimental: nasal administration

nasal administration of dexmedetomidine 1μg/kg

Drug: Dexmedetomidine
oral, intravenous and nasal administration of Dexmedetomidine

Outcome Measures

Primary Outcome Measures

  1. Dexmedetomidine pharmacokinetic curve [120 min DEX pharmacokinetics]

    Dexmedetomidine (DEX) blood concentration are detected at 8 time points (before DEX administration, 10 min, 20 min, 30 min, 45 min, 60min, 90min and 120 min after administration) in the groups of oral, intravenous and nasal drops administration of DEX. 3 ml arterial blood was collected at each time point. The blood samples are detected by mass spectrometer to detect blood concentration of DEX. Then DEX pharmacokinetic curve is made according to the DEX blood concentration.

Secondary Outcome Measures

  1. Effect of sedation [10min after administration]

    Evaluated with Ramsay sedation scale Score Response Anxious or restless or both Cooperative, orientated and tranquil Responding to commands Brisk response to stimulus Sluggish response to stimulus No response to stimulus

  2. Evaluation of surgical field [30min after administration]

    Surgical field was evaluated according to the report Boezaart A.P.,van der Merwe J.,Coetzee A. Comparison of sodium nitroprusside- and esmolol-induced controlled hypotension for functional endoscopic sinus surgery. Can J Anaesth,1995,42(5 Pt 1): 373-376. 0 No bleeding. Slight bleeding - no suctioning of blood required. Slight bleeding - occasional suctioning required. Surgical field not threatened. Slight bleeding - frequent suctioning required. Bleeding threatens surgical field a few seconds after suction is removed. Moderate bleeding - frequent suctioning required. Bleeding threatens surgical field directly after suction is removed. Severe bleeding - constant suctioning required. Bleeding appears faster than can be removed by suction. Surgical field severely threatened and surgery not possible.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 45 participants who undergo tympanoplasty would be enrolled after signment the informed consent.
Exclusion Criteria:
  • The participants were excluded with any diseases about respiration, circulation, liver and kidney.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Eye, Ear, Nose and Throat Hospital Shanghai Shanghai China 200031

Sponsors and Collaborators

  • Eye & ENT Hospital of Fudan University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jinhong Wu, Principal Investigator, Eye & ENT Hospital of Fudan University
ClinicalTrials.gov Identifier:
NCT03800641
Other Study ID Numbers:
  • EyeEntFudan
First Posted:
Jan 11, 2019
Last Update Posted:
Jan 11, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jinhong Wu, Principal Investigator, Eye & ENT Hospital of Fudan University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 11, 2022